



FDA ADVISORY  
No. 2021-1945


29 JUL 2021

TO: GENERAL CONSUMING PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of the following Unauthorized Cosmetic Products:

1. HADA LABO PREMIUM HYALURONIC ACID MILK
2. HADA LABO KOI-GOKUJYUN UV WHITE GEL SPF 50+ PA ++++
3. HADA LABO SHIROJYUN WHITENING LOTION RICH

The Food and Drug Administration (FDA) warns the public from purchasing and using the following unauthorized cosmetic products (Refer to the image below):



Source: <https://www.lazada.com.ph/products/hada-labo-premium-hyaluronic-acid-milk-140ml-i326128092-s1506156808.html>

Figure 1. Unauthorized Product Hada Labo Premium Hyaluronic Acid Milk



### [Hada Labo] Koi-Gokujyun UV White Gel SPF 50+ PA++++ 90g Moisturizer for Face

★★★★★ 4 Ratings

Brand: Hada Labo | More Skin Care from Hada Labo

**WITH FREE SHIPPING VOUCHER!  
COLLECT IT BELOW!**

**₱965.00**

~~₱1,199.00~~ -20%

Promotions

Buy ₱199.00 cap at ₱50.00 off

Over ₱2,299.00 to get free gift

Source: <https://www.lazada.com.ph/products/hada-labo-koi-gokujyun-uv-white-gel-spf-50-pa-90g-i982616854.html>

Figure 2. Unauthorized Product Hada Labo Koi-Gokujyun Uv White Gel Spf 50+ Pa +++++



### Hada Labo Shirojyun Whitening Lotion Rich 170mL Toner

★★★★★ 16 Ratings | 1 Answered Questions

Brand: Hada Labo | More Skin Care from Hada Labo

**₱690.00**

~~₱850.00~~ -19%

Promotions

Buy ₱199.00 cap at ₱50.00 off

Over ₱2,299.00 to get free gift



Quantity  Only 4 items left

Source: <https://www.lazada.com.ph/products/hada-labo-shirojyun-whitening-lotion-rich-170ml-i326106277.html>

Figure 3. Unauthorized Product Hada Labo Shirojyun Whitening Lotion Rich

The abovementioned products were verified by FDA through postmarketing surveillance and shows no valid Certificate of Product Notification (CPN) as of 27 July 2021. Pursuant to Book II, Article I, Section 1 (a) of the Rules and Regulations Implementing Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising, or sponsorship of any health product without the proper authorization from the FDA is prohibited.

Since the abovementioned unauthorized cosmetic product has not gone through the notification process of the FDA, the agency cannot assure their quality and safety. The use of such violative product may pose health risks to consumers.

Potential hazards may come from ingredients that are not allowed to be part of a cosmetic product or from the contamination of heavy metals. The use of substandard and possibly adulterated cosmetic products may result to adverse reactions including, but not limited to, skin irritation, itchiness, anaphylactic shock and organ failure.

In light of the foregoing, the public is advised not to purchase the aforementioned violative cosmetic product. Always check if a product is notified with the FDA by using the FDA Verification Portal feature accessible at <https://verification.fda.gov.ph> which may be used by typing in the name of the product before the purchase and/or using the cosmetic products.

All concerned establishments are warned not to distribute violative cosmetic product until they have fully complied with the rules and regulation of the FDA.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of their jurisdiction.

To report any sale, distribution, complaint and/or adverse event on the use of the violative cosmetic products, the online reporting facility, **eReport** can be accessed at [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph), or call us at the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR) hotline **(02) 8857-1900 loc. 8113 or 8107**.

Dissemination of this advisory to all concerned is hereby requested.

  
**ROLANDO ENRIQUE D. DOMINGO, MD**  
Director General

DTN: 20210713144143